Skip to main content
Premium Trial:

Request an Annual Quote

"Just PubMed It" Could Catch On…

DrugMonkey waxes philosophical about "Google" morphing into a verb and how PubMed hasn't quite reached that point. Researchers, especially those at large, well-funded universities, can go to PubMed with a query and come away with relevant journal articles. But not everyone has that luxury, such as researchers in the developing world and even professors and students at smaller colleges in the developed world, and that's where DrugMonkey pipes up for open access. "The ability to pubmed primary research articles is a default part of our household. Perhaps not used as extensively as the google, but certainly an important and palpable feature of our normal lives. I see no reason not to extend this benefit to everyone," says the post.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.